Long-term effects of safinamide on dyskinesia in mid- to late-stage Parkinson's disease: A post-hoc analysis

Journal of Parkinson's Disease

Volumn 5, Issue 3, 2015, Pages 475-481

  Cattaneo, Carlo ^a   Ferla, R La ^a   Bonizzoni, Erminio ^b   Sardina, Marco ^a  

^a Zambon Group SpA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Dyskinesia; Levodopa; Parkinson's disease; Safinamide

Indexed keywords

AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; SAFINAMIDE; ALANINE; ANTIPARKINSON AGENT; BENZYLAMINE DERIVATIVE;

ADD ON THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; DYSKINESIA RATING SCALE SCORE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PARKINSON DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANK SUM TEST; SCORING SYSTEM; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; DYSKINESIAS; FOLLOW UP; MULTICENTER STUDY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ALANINE; ANTIPARKINSON AGENTS; BENZYLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSKINESIAS; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84941779974     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-150569     Document Type: Article

References (28)

1. LeWitt PA (2009) Levodopa therapeutics for Parkinson's disease: New developments. Parkinsonism Relat Disord, 15(Suppl 1), S31-S34.
2. Hauser RA (2009) Levodopa: Past, present, and future. Eur Neurol, 62, 1-8.
3. Ahlskog JE, & Muenter MD (2001) Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord, 16, 448-458.
4. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ, & Quality Standards Subcommittee of the American Academy of N (2006) Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the quality standards subcommittee of the american academy of neurology. Neurology, 66, 983-995.
5. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, & Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord, 22, 1379-1389; quiz, 1523.
6. Hinson VK (2010) Parkinson's disease and motor fluctuations. Curr Treat Options Neurol, 12, 186-199.
7. Fox SH (2013) Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs, 73, 1405-1415.
8. Blandini F, Porter RH, & Greenamyre JT (1996) Glutamate and Parkinson's disease. Mol Neurobiol, 12, 73-94.
9. Borgohain R, & Kandadai RM (2013) Safinamide: A novel anti-Parkinsonian drug with multiple actions. Neurodegener Dis Manag, 3, 231-240.
10. Chase TN, Bibbiani F, & Oh JD (2003) Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res, 5, 139-146.
11. Schapira AH, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, Lucini V, Giuliani R, Anand R, & Study I (2013) Long-term efficacy and safety of safinamide as addon therapy in early Parkinson's disease. Eur J Neurol, 20, 271-280.
12. Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, Bonuccelli U, Van Dijk A, Cattaneo C, Sala P, Fariello RG, & Safinamide Parkinson's Study G (2004) Improvement of motor function in early Parkinson disease by safinamide. Neurology, 63, 746-748.
13. Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, Giuliani R, Anand R, & Study I (2012) A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord, 27, 106-112.
14. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, & Study I (2014) Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord, 29, 229-237.
15. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, & Study I (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord, 29, 1273-1280.
16. Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, &FarielloRG(2006) Safinamide: From molecular targets to a newanti-Parkinson drug. Neurology, 67, S18-S23.
17. Chazot PL (2007) Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs, 8, 570-579.
18. Gregoire L, Jourdain VA, Townsend M, Roach A, & Di Paolo T (2013) Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord, 19, 508-514.
19. Kulisevsky J (2014) Emerging role of safinamide in Parkinson's disease therapy. Eur Neurolog Review, 9, 3-7.
20. Muller T (2013) Current status of safinamide for the drug portfolio of Parkinson's disease therapy. Expert Rev Neurother, 13, 969-977.
21. Caccia C, Salvati P, Rossetti S, &AnandR(2008) Safinamide: Modulation of dopaminergic and glutamatergic system. Mov Disord, 2008, S22-S23.
22. Pevarello P, Bonsignori A, Dostert P, Heidempergher F, Pinciroli V, Colombo M, McArthur RA, Salvati P, Post C, Fariello RG, & Varasi M (1998) Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. J Med Chem, 41, 579-590.
23. Cattaneo C, Caccia C, Marzo A, Maj R, & Fariello RG (2003) Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol, 26, 213-217.
24. Onofrj M, Bonanni L, & Thomas A (2008) An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs, 17, 1115-1125.
25. Goetz CG, Stebbins GT, Shale HM, Lang AE, Chernik DA, Chmura TA, Ahlskog JE, & Dorflinger EE (1994) Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter-and intrarater reliability assessment. Mov Disord, 9, 390-394.
26. Marcus R, Peritz E, & Gabriel KR (1976) On closed testing procedures with special reference to ordered analysis of variance. Biometrika, 63, 665-660.
27. Brotchie JM (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord, 20, 919-931.
28. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, & Chase TN (2000) AMPA receptor blockade improves levodopainduced dyskinesia in MPTP monkeys. Neurology, 54, 1589-1595.